Association Between BRAFV6OOE Mutation and Mortality in Patients With Papillary Thyroid Cancer.

The article discusses research which investigated the relationship between BRAF V600E mutation and papillary thyroid cancer (PTC)-related mortality. BRAF V600E is a prominent oncogene in PTC. A total of 1,849 patients with a median age of 46 years are considered in the study. Findings revealed 5.3% mortality in BRAF-positive versus mutation-negative patients. Deaths per 1000 person-years in the analysis of PTC conventional variant were 11.80 versus 2.25 in BRAF-positive versus mutation-negative patients. A higher BRAF-associated mortality was observed in clinicopathological subcategories.